News Sentiment

VNDA sentiment intelligence

Vanda Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.24 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.5% over one week, +6.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Vanda Reports Positive Opinion for Imsidolimab Orphan Drug Label

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.5% Price digesting
Trend fit Trend inactive 6.3% over four weeks
Fair value 20.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 34
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 8
Stock Titan 7
simplywall.st 5
PR Newswire 4
Stocktwits 4
MT Newswires 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 20
Regulatory and legal 7
Deals and strategy 3
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
TradingView Direct company coverage

Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – FWB:VM4

The article presents the Enterprise Value to EBITDA forward for Vanda Pharmaceuticals Inc. (FWB:VM4) on the Frankfurt Stock Exchange. It provides financial data for this specific metric and indicates that the market was closed with no trades at the time of publication. The conten

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. – LSX:A0JJT3

This article focuses on the "Enterprise value to revenue forward" metric for Vanda Pharmaceuticals Inc. (LSX:A0JJT3). It is presented within the context of financial data available on TradingView, specifically under the company's financials section. The content primarily lists an

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:40
Source
TradingView
Barchart.com Direct company coverage

Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda

This report from DelveInsight highlights the Gastroparesis treatment pipeline for 2026, detailing over 10 therapies from 8+ companies including CinDome Pharma, Evoke Pharma, and Vanda Pharmaceuticals. The report provides an overview of clinical trials, mechanisms of action, and r

Tone
Positive 66/100
Event
Regulatory and legal
Published
26 Jun 2026 13:39
Source
Barchart.com
MarketBeat Direct company coverage

Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jun 2026

Vanda Pharmaceuticals (VNDA) saw a 2.61% increase in its short interest, reaching 6.99 million shares sold short as of June 15, 2026, representing 13.01% of its public float. The short interest ratio is currently 7.8 days to cover, suggesting it would take approximately 7.8 days

Tone
Negative 40/100
Event
Market update
Published
26 Jun 2026 06:40
Source
MarketBeat
TradingView Direct company coverage

Vanda Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VNDA)

This article provides an overview of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) stock performance, financials, and analyst forecasts. It covers key metrics like current price, market capitalization, earnings, revenue, and future price predictions from analysts, along with historic

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 17:40
Source
TradingView